Health professionals' preferences with the use of pegfilgrastim on-body injector at oncology centers in 8 cities in Colombia.

ABSTRACT:

Background

Febrile neutropenia associated with some chemotherapy regimens can lead to potentially fatal complications and high health care costs. Administration of pegfilgrastim using an On-Body Injector (OBI) may be more convenient for cancer patients and physicians in countries with limited access to high-complexity healthcare. This study aims to describe physician and nurse preferences regarding different options for administration of pegfilgrastim at cancer centers, the chemotherapy schemes for which pegfilgrastim is most frequently prescribed and how healthcare providers prioritize certain administration schemes according to patients' access to healthcare services.

Methods

Observational, descriptive, cross-sectional study and survey, conducted between 2019 and 2020, to

SUBMITTER: Larrarte-Gonzalez MA 

PROVIDER: S-EPMC10207821 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature